5.1 COPD: Diagnosis, GOLD Classification & Initial Pharmacotherapy

Obstructive airway disorders represent one of the highest-yield domains on the ABIM Internal Medicine certification examination. Mastery requires a deep understanding of spirometric interpretation, the 2024 Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines, mortality-reducing interventions, exacerbation triage and pharmacotherapy, the 2024 Global Initiative for Asthma (GINA) Track 1 Single Maintenance and Reliever Therapy (SMART) paradigm, and the targeted application of biologic agents.

1. Chronic Obstructive Pulmonary Disease (COPD): Diagnosis & Pathophysiology

COPD is a heterogeneous lung condition characterized by chronic respiratory symptoms (dyspnea, cough, sputum production) resulting from airway abnormalities (bronchitis, bronchiolitis) and/or alveolar abnormalities (emphysema) that cause persistent, often progressive airflow limitation.

Diagnostic Spirometry

• Gold Standard Diagnostic Criterion: A post-bronchodilator FEV1/FVC ratio < 0.70 (fixed ratio) measured via spirometry 15–30 minutes after inhaling 400 mcg of albuterol confirms persistent airflow limitation.
• Unlike asthma, the airflow obstruction in COPD is typically irreversible or only partially reversible.
• Alpha-1 Antitrypsin (AAT) Deficiency Screening: The WHO and GOLD guidelines recommend screening all patients with COPD at least once with a serum AAT level. Test specifically in patients who present at age <45 years, non-smokers, or those with basilar-predominant panacinar emphysema. Normal genotype is PiMM; severe deficiency is PiZZ (serum AAT <11 µmol/L or <57 mg/dL). Intravenous human alpha-1 proteinase inhibitor augmentation slows emphysema progression.

Pathophysiologic Mechanisms

• Small Airway Disease (Obstructive Bronchiolitis): Chronic inflammation of small conducting airways (<2 mm diameter), goblet cell hyperplasia, mucus hypersecretion, peribronchiolar fibrosis, and luminal plugging.
• Emphysema: Destruction of gas-exchanging respiratory bronchioles and alveolar walls without obvious fibrosis, mediated by an imbalance between neutrophil elastases/proteases and antiproteases (e.g., alpha-1 antitrypsin), combined with oxidative stress from cigarette smoke or biomass exposure.
  • Centriacinar (Centrilobular) Emphysema: Involves the proximal respiratory bronchioles; strongly associated with cigarette smoking; predominant in the upper lung zones.
  • Panacinar (Panlobular) Emphysema: Uniform destruction of the entire acinus from respiratory bronchiole to alveoli; characteristic of Alpha-1 Antitrypsin deficiency; predominant in the lower lung zones.
• Dynamic Hyperinflation & Air Trapping: Loss of elastic recoil and premature expiratory airway collapse lead to incomplete lung emptying during expiration, resulting in elevated functional residual capacity (FRC), elevated residual volume (RV), flattened diaphragms, increased work of breathing, and exertional dyspnea.

2. GOLD 2024 Classification & Staging

COPD classification combines spirometric severity (GOLD Grades 1–4) with symptom burden and exacerbation risk (Refined ABE Assessment).

Spirometric Classification of Airflow Limitation (Post-Bronchodilator FEV1)

All categories require a post-bronchodilator FEV1/FVC < 0.70:

The 2024 Refined GOLD ABE Assessment Framework

In the updated GOLD framework, historical Groups C and D are merged into Group E to emphasize the clinical importance and therapeutic urgency of exacerbation prevention.

• Symptom Assessment Tools:
  • mMRC (Modified Medical Research Council) Dyspnea Scale: Grade 0 (dyspneic only on strenuous exercise) to Grade 4 (too dyspneic to leave house or breathless dressing). Cutoff: <2 vs. >=2.
  • CAT (COPD Assessment Test): Multi-item health status questionnaire (score 0–40). Cutoff: <10 vs. >=10.
• Exacerbation History Classification:
  • Low Risk: 0 or 1 moderate exacerbation in the past 12 months (not leading to hospital admission).
  • High Risk (Group E): >=2 moderate exacerbations OR >=1 exacerbation requiring hospital admission in the past 12 months.

GOLD 2024 Initial Pharmacotherapy Regimens

1. Group A (Low Symptoms, Low Exacerbation Risk):
   • Initial Regimen: A single bronchodilator — either short-acting (SABA or SAMA PRN) or long-acting (LABA or LAMA).
2. Group B (High Symptoms, Low Exacerbation Risk):
   • Initial Regimen: LABA + LAMA combination (e.g., Tiotropium/Olodaterol, Umeclidinium/Vilanterol, Glycopyrrolate/Formoterol). Dual long-acting bronchodilation is superior to monotherapy for symptom relief, lung function improvement, and exercise tolerance.
3. Group E (High Exacerbation Risk, regardless of symptom score):
   • Initial Regimen: LABA + LAMA combination.
   • Role of Inhaled Corticosteroids (ICS): Add an ICS (initiating LABA + LAMA + ICS triple therapy) as first-line if blood eosinophils are >= 300 cells/mcL.
   • If blood eosinophils are 100–299 cells/mcL, initiate LABA + LAMA; add ICS if recurrent exacerbations persist despite dual bronchodilation.
   • If blood eosinophils are < 100 cells/mcL, ICS therapy offers minimal benefit and significantly increases the risk of pneumonia; avoid ICS.

Follow-up Escalation & Targeted Second-Line Agents

• Roflumilast (PDE4 Inhibitor): 500 mcg PO daily. Indicated as add-on therapy for patients with FEV1 < 50% predicted, chronic bronchitis phenotype (frequent cough and sputum), and >=1 hospital admission for exacerbation in the past year on optimal inhaled therapy. Side effects: weight loss, nausea, diarrhea, neuropsychiatric symptoms (depression, insomnia).
• Macrolide Maintenance (Azithromycin): Azithromycin 250 mg daily or 500 mg three times weekly for 1 year in former smokers with persistent exacerbations on triple therapy. Reduces exacerbation frequency. Pre-treatment evaluation: baseline 12-lead ECG (confirm QTc < 450 ms in men, < 470 ms in women), audiometry (risk of sensorineural ototoxicity), and sputum mycobacterial culture (to avoid inducing macrolide resistance in occult Mycobacterium avium complex).